



REQUEST FOR QUOTATION no. 53/2024/M/CELONKO2.0 dated 10.05.2024r.

for Celon Pharma with its registered office in Kiełpin

In connection with the implementation of the project „**Clinical development of an innovative CPL110 inhibitor in FGFR-dependent solid tumors**”, no 2022/ABM/06/00003 co-financed from the state budget by the Medical Research Agency.

DATE OF PUBLICATION: 10.05.2024r.

ORDERING PARTY: Celon Pharma S.A., ul. Ogrodowa 2A, 05-092 Kiełpin

LOCATION: Kiełpin

PARTIAL OFFERS ALLOWED: YES

VARIANTS ALLOWED: NO

DEADLINE FOR THE IMPLEMENTATION OF THE CONTRACT: no later than by 31 July 2024

I. ORDERING PROCEDURE:

- This order is not subject to the provisions of the Act of 11 September 2019, Public Procurement Law;
- This contract award procedure shall be conducted with due observance of the principles of competitiveness, openness, transparency and equal access;
- The Ordering Party reserves the right to cancel the proceedings at any stage, without giving reasons;
- The Ordering Party shall inform Suppliers about any changes made by publishing relevant information on its website;
- The Ordering Party reserves itself the right to request additional information, documents or explanations;
- In justified cases, before the deadline for submitting tenders, the Ordering Party reserves the right to modify or change the content of the invitation to submit tenders;
- This invitation to tender imposes no obligation on Celon Pharma SA to conclude a contract.

CELON PHARMA S.A.

Siedziba: ul. Ogrodowa 2A, 05-092 Łomianki / Kiełpin, **Centrum Badawczo Rozwojowe:** ul. Marymoncka 15, 05-152 Kazuń Nowy

Tel.: +48 22 751 59 33; e-mail: info@celonpharma.com, www.celonpharma.com

Organ rejestrowy: Sąd Rejonowy dla m. st. Warszawy, XIV Wydział Gospodarczy Krajowego Rejestru Sądowego


Prezes Zarządu: Maciej Wieczorek, **Wysokość kapitału zakładowego:** 5.105.650 PLN, **KRS:** 0000437778, **NIP:** 1181642061, **BDO:** 00010958




II. DESCRIPTION OF THE SUBJECT OF REQUEST FOR QUOTATION NO. 53/2024/M/CELONKO2.0

CPV code: 33696300-8

Set 1.

No.	Description	Quantity															
1.	<p>5-[2-(3,5-dimethoxyphenyl)ethyl]-1H-pyrazole-3-carboxylic acid CAS: 1627826-38-3</p>  <table border="1"><thead><tr><th>Test</th><th>Description/Limit</th><th>Determination method</th></tr></thead><tbody><tr><td>Description</td><td>From white to beige solid substance</td><td>visual estimation</td></tr><tr><td>Identity</td><td>Spectrum of tested substance should comply with the reference spectrum</td><td>IR or NMR method</td></tr><tr><td>Related substances: - single unknown impurity - total impurities</td><td>$\leq 1.5\%$ $\leq 3.0\%$</td><td>HPLC UV</td></tr><tr><td>Loss on drying</td><td>$\leq 1.0\%$</td><td>TGA method</td></tr></tbody></table>	Test	Description/Limit	Determination method	Description	From white to beige solid substance	visual estimation	Identity	Spectrum of tested substance should comply with the reference spectrum	IR or NMR method	Related substances: - single unknown impurity - total impurities	$\leq 1.5\%$ $\leq 3.0\%$	HPLC UV	Loss on drying	$\leq 1.0\%$	TGA method	10kg
Test	Description/Limit	Determination method															
Description	From white to beige solid substance	visual estimation															
Identity	Spectrum of tested substance should comply with the reference spectrum	IR or NMR method															
Related substances: - single unknown impurity - total impurities	$\leq 1.5\%$ $\leq 3.0\%$	HPLC UV															
Loss on drying	$\leq 1.0\%$	TGA method															

Set 2.

No.	Description	Quantity
1.	<p>5-(4-methylpiperazin-1-yl)-2-nitroaniline CAS: 23491-48-7</p> 	15kg

CELON PHARMA S.A.

Siedziba: ul. Ogrodowa 2A, 05-092 Łomianki / Kiełpin, Centrum Badawczo Rozwojowe: ul. Marymoncka 15, 05-152 Kazuń Nowy
Tel.: +48 22 751 59 33; e-mail: info@celonpharma.com, www.celonpharma.com

Organ rejestrowy: Sąd Rejonowy dla m. st. Warszawy, XIV Wydział Gospodarczy Krajowego Rejestru Sądowego

Prezes Zarządu: Maciej Wieczorek, Wysokość kapitału zakładowego: 5.105.650 PLN, KRS: 0000437778, NIP: 1181642061, BDO: 00010958



Test	Description/Limit	Determination method
Description	From light to dark yellow solid substance	visual estimation
Identity	Spectrum of tested substance should comply with the reference spectrum	IR or NMR method
Related substances: - single unknown impurity - total impurities	$\leq 1.0\%$ $\leq 3.0\%$	HPLC UV
Loss on drying	$\leq 1.0\%$	TGA method

1. Due to the continuation of research work under the project, their specificity and unique nature of the reagents/materials used in the research process will significantly affect the shape of the B+R work carried out, in the description of the subject of the contract for technical reasons of an objective nature, the catalog number of the product/s is given;
2. Due to the uniqueness, strictly defined methodology of projects, scientific research and experiments and the need to maintain the continuity and repeatability of research carried out by the Ordering Party, the Supplier offering products equivalent to the products described in the request for proposal is obliged to:
 - demonstration on the basis of technical documentation/safety data sheets/etc. and a written declaration that the equivalent products offered by it meet the requirements allowing for the continuation of scientific research of the Ordering Party without the need to perform additional activities (procedures), including e.g. calibration of devices, validation of developed laboratory methods;
 - demonstrate (by means of a written declaration in the submitted tender) that the equivalent products offered will not result in an increase in costs due to the need to purchase additional products and other consumables;
 - accept – in the form of a written declaration – liability for damage to equipment resulting from the use of offered and supplied equivalent products, on the basis of an opinion issued by an authorized service of the equipment manufacturer.
3. The Supplier shall pay the Ordering Party contractual penalties:
 - for delay in the delivery date of the subject of the order, for each commenced day of delay, unless the delay is due to the fault of the Ordering Party;

CELON PHARMA S.A.

Siedziba: ul. Ogrodowa 2A, 05-092 Łomianki / Kiełpin, **Centrum Badawczo Rozwojowe:** ul. Marymoncka 15, 05-152 Kazuń Nowy

Tel.: +48 22 751 59 33; e-mail: info@celonpharma.com, www.celonpharma.com

Organ rejestrowy: Sąd Rejonowy dla m. st. Warszawy, XIV Wydział Gospodarczy Krajowego Rejestru Sądowego

Prezes Zarządu: Maciej Wieczorek, **Wysokość kapitału zakładowego:** 5.105.650 PLN, **KRS:** 0000437778, **NIP:** 1181642061, **BDO:** 00010958



- where the results of studies carried out with an equivalent product are not as expected;
- the supplier agrees to deduct the amount of contractual penalties directly when paying the invoice for the delivery.

III. CRITERIA FOR THE SELECTION OF TENDERS

1. Price (C) – 100 points (100%)

Method of assessment:

Criterion	Weight (%)	Points	Evaluation formula
Price	100%	100 pkt	$C = \frac{\text{Lowest quoted price}}{\text{Quoted price}} \times 100 \text{ points}$

The total number of points that a given bid will receive will be calculated according to the following formula:

$$L = C$$

L – total number of points;

C – points obtained in the criterion "Price".

IV. ADDRESS AND DEADLINE FOR SUBMISSION OF OFFERS

1. The offer should be sent to the e-mail address: przemyslaw.pietrasiuk@celonpharma.com or sent by traditional mail or courier to the following address: Celon Pharma S.A., Ul. Marymoncka 15, 05-152 Kazuń Nowy;
2. The offer must be submitted no later than **20.05.2024**. In the case of sending the offer by traditional mail or courier, the offer shall be deemed submitted if it has been received by the Ordering Party no later than on the date indicated as the deadline for submitting offers;
3. Bids submitted after the above deadline will not be considered;
4. Offers will be evaluated no later than **07.06.2024**;
5. Offers submitted in a foreign currency will be converted according to the NBP exchange rate as of the date of preparation of the protocol of the request for quotation;
6. Information on the selection of offers will be published on the Ordering Party's website: www.celonpharma.com.

CELON PHARMA S.A.

Siedziba: ul. Ogrodowa 2A, 05-092 Łomianki / Kiełpin, Centrum Badawczo Rozwojowe: ul. Marymoncka 15, 05-152 Kazuń Nowy

Tel.: +48 22 751 59 33; e-mail: info@celonpharma.com, www.celonpharma.com

Organ rejestrowy: Sąd Rejonowy dla m. st. Warszawy, XIV Wydział Gospodarczy Krajowego Rejestru Sądowego

Prezes Zarządu: Maciej Wieczorek, Wysokość kapitału zakładowego: 5.105.650 PLN, KRS: 0000437778, NIP: 1181642061, BDO: 00010958



V. PRESENTATION OF OFFERS

1. Each Bidder may submit only one bid in Polish or English;
2. The offer must include:
 - The number of the request for quotation,
 - Date of preparation of the offer,
 - The details of the Tenderer: address, telephone number, e-mail address, Tax Identification Number (NIP) (if available),
 - Include details of the compliance of the proposed product with the specification,
 - If the offer was submitted by the Tenderer operating in Poland: net price, gross price and tax due,
 - If the offer was submitted by the Bidder operating outside the Polish: net price and information on the absence of VAT and other taxes.
3. **Together with the offer, the " Declaration of no personal or capital connections with the Ordering Party " should be submitted, which is Annex 1 to this request for quotation;**
4. **The offer must remain valid until 07.06.2024;**
5. The costs of preparing the offer shall be borne by the Tenderer;
6. **The payment deadline for each invoice must be at least 30 days;**
7. **The offer must be signed by persons authorized to represent the Contractor/Supplier (according to the National Court Register or power of attorney).**

VI. CONCLUSION OF THE CONTRACT

The tenderer whose offer will be assessed as the most advantageous is obliged to conclude a contract with the Ordering Party. If the Tenderer whose offer has been selected evades the conclusion of the contract, the Contracting Authority has the right to select the next Tenderer whose offer was the most advantageous of the remaining offers.

Notice:

- Due to the need to maintain the continuity of research, the Contracting Authority provides for the possibility of placing a supplementary order in the amount not exceeding 50% of the contract value specified in the contract concluded with the selected Contractor/Supplier;
- If it is necessary to perform additional orders not covered by the basic contract, the Contracting Authority reserves the right to award a supplementary contract to the Tenderer if the value of each subsequent change does not exceed 50% of the value of the basic contract specified in the contract concluded with the Tenderer;

CELON PHARMA S.A.

Siedziba: ul. Ogrodowa 2A, 05-092 Łomianki / Kiełpin, **Centrum Badawczo Rozwojowe:** ul. Marymoncka 15, 05-152 Kazuń Nowy

Tel.: +48 22 751 59 33; e-mail: info@celonpharma.com, www.celonpharma.com

Organ rejestrowy: Sąd Rejonowy dla m. st. Warszawy, XIV Wydział Gospodarczy Krajowego Rejestru Sądowego

Prezes Zarządu: Maciej Wieczorek, **Wysokość kapitału zakładowego:** 5.105.650 PLN, **KRS:** 0000437778, **NIP:** 1181642061, **BDO:** 00010958



- The Contracting Authority allows for the possibility of cancelling the order or resigning from the order of goods and services included in the partial procedure or from the whole procedure, in the event of failure to obtain funds for the performance of this contract or in other cases when the performance of the contract will not be in the interest of the Ordering Party;
- Entities related to the Contracting Party either personally or by capital are excluded from participation in this procurement. Capital or personal relationships are understood as mutual relations between the Contracting Party or persons authorised to contract obligations on behalf of the Contracting Party or persons performing on behalf of the Contracting Party activities related to the conduct of the procedure for selecting a contractor and the contractor, consisting in particular of the following:
 - a) participation in a company as a partner in a civil law partnership or a partnership,
 - b) owning at least 10% of shares as long as the lower limit does not result from legal provisions or was not defined by IZ PO,
 - c) fulfilling the duties of member of the supervisory body or as manager, proxy or power of attorney,
 - d) being married, a direct family member, direct affinity, second-level relative or second degree affinity in lateral line or in relation to adoption, care or guardianship.
- The contracting authority allows the possibility of negotiating the presented offer;
- The Contracting Party reserves the right to amend the agreement concluded with the awarded tenderer as a result of the procurement for the following reasons:
 - a) justified changes in the manner of performance of the subject-matter of the order,
 - b) objective reasons beyond the control of the Contracting Party or tenderer,
 - c) changes in legal regulations in force on the day of signing the contract,
 - d) force majeure,
 - e) occurrence of another obstacle, beyond the control of the tenderer, which prevents the performance of works,
 - f) in the event of changes to the Subject of the Agreement exceeding the material and/or financial scope indicated in the Tender, the Parties undertake that such changes will be introduced by way of an amending Annex and according to the "Guidelines on the eligibility of expenditure under the European Regional Development Fund, the European Social Fund and the Cohesion Fund for 2014-2020".
- In connection with the entry into force of the Act of April 13, 2022 on special solutions in the field of counteracting aggression against Ukraine and serving the protection of national security (Journal of Laws, item 835), entities or citizens from the Russian Federation are excluded from participation in these proceedings, while subject to the sanctions specified in Art. 1 above of the Act, provided that on the day of submitting the offer they are on the list of persons and entities against which sanction measures should be applied, kept on the website of the Public Information Bulletin of the Minister of Internal Affairs and Administration.

CELON PHARMA S.A.

Siedziba: ul. Ogrodowa 2A, 05-092 Łomianki / Kiełpin, **Centrum Badawczo Rozwojowe:** ul. Marymoncka 15, 05-152 Kazuń Nowy
Tel.: +48 22 751 59 33; e-mail: info@celonpharma.com, www.celonpharma.com

Organ rejestrowy: Sąd Rejonowy dla m. st. Warszawy, XIV Wydział Gospodarczy Krajowego Rejestru Sądowego

Prezes Zarządu: Maciej Wieczorek, **Wysokość kapitału zakładowego:** 5.105.650 PLN, **KRS:** 0000437778, **NIP:** 1181642061, **BDO:** 00010958